# Effect of Evolocumab on Vascular Function

> **NCT03626831** · PHASE4 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 105 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Evolocumab Prefilled Syringe
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03626831
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-07-12
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626831, "Effect of Evolocumab on Vascular Function". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03626831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*